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IntroductIon
Pain is commonly reported as the most relevant symptom 
for endometriosis patients (1, 2) and most women with 
symptomatic endometriosis experience some symptoms 
of pain associated with their menstrual cycle (3). the ways 
to measure pain symptoms in clinical trials differ substan-
tially: pain scales used in past and recent endometriosis 
How can we measure endometriosis-associated 
pelvic pain?
Christoph Gerlinger1, Ulrike Schumacher2, René Wentzeck1, Kerstin Uhl-Hochgräber3,  
Erich F. Solomayer4, Heinz Schmitz5, Thomas Faustmann6, Christian Seitz5
1Bayer Healthcare, Global Biostatistics, Berlin - Germany
2Jenapharm and Zentrum für Klinische Studien, universitätsklinikum Jena, Jena - Germany
3Bayer Healthcare, Global Health Economics and outcomes research, Berlin - Germany
4university of Saarland, department of obstetrics, Gynecology, and reproductive Medicine, Homburg/Saar - Germany
5Bayer Healthcare, Global clinical development, Berlin - Germany
6Bayer Healthcare, Global Medical Affairs Women’s Healthcare, Berlin - Germany
AbstrAct
Purpose: The aim of our work was to explore which of the most commonly used pain scales is best 
suited to assess treatment success in endometriosis therapy and, therefore, qualifies best to be used 
as primary endpoint for clinical studies in this indication.
Methods: We compared patient’s responses on the different pain scales Visual Analog Scale, Bib-
eroglu and Behrman Score, and SF-36 Bodily Pain Subscale with the Clinical Global Impression score. 
Parametric and non-parametric correlation coefficients and effect sizes were calculated.
results: A total of 428 patients with endometriosis-associated pelvic pain from three studies were 
included in our analyses. Their mean age was 31.4±6.3 years and their mean pain score on the visual 
analog scale was 58.1±21.9 at baseline. The highest correlation with the Clinical Global Impression 
score was observed for the visual analog scale followed by the B&B pelvic pain item. The highest ef-
fect sizes were found for dysmenorrhea and SF-36 bodily pain subscale followed by the visual analog 
scale.
conclusions: A general measure of endometriosis-related pain can be recommended as primary end-
point in clinical trials to assess painful symptoms of endometriosis. In addition, a disease-specific 
quality of life tool is recommended to help interpret impact on patients’ daily activities. 
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trials include, among others, the Biberoglu & Behrman 
Score (B&B) (4), the Visual Analog Scale (VAS) (5), and 
the numerical rating Scale (nrS) (6). this problem was 
recently addressed by an expert group who gave recom-
mendations regarding endpoints to be included in clinical 
trials for endometriosis (7). the varied nature limits direct 
comparison of the trial results and makes meta-analyses 
difficult. the situation is further complicated by the differ-
doI: 10.5301/JE.2012.9725
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group study to investigate the efficacy and safety of daily oral 
administration of 2 mg dienogest (dnG) versus intramuscular 
administration of 3.75 mg Leuprorelin Acetate (LA) every four 
weeks for the treatment of symptomatic endometriosis over 24 
weeks. Study 2 (11) was a multicenter, double-blind, random-
ized, placebo-controlled, parallel-group study to investigate the 
efficacy and safety of daily oral administration of 2 mg dnG 
tablets for the treatment of endometriosis over 12 weeks. Study 
3 (clinicaltrials.gov Identifier: nct00185341) compared an ex-
perimental treatment (Et) to placebo (PL) and used a design 
almost identical to study 2. Et in study 3 was revealed to be no 
more efficacious than PL. For the purpose of this analysis, Et 
was therefore pooled with PL. Patients on LA were excluded 
from our analyses because of the expected confounding of 
the QoL scores with the typical side effects of LA, such as hot 
flushes and amenorrhea, which precluded the pooling of the 
LA-treated patients with those of the other groups. 
the study protocols were approved by local independent Eth-
ics committees and all participants provided written informed 
consent before study enrolment. Studies were performed in ac-
cordance with the amended version of the declaration of Hel-
sinki and complied with Good clinical Practice.
Patients
In all studies, 18 to 45-year-old women between menarche and 
menopause, and in good general health except for endometrio-
sis, were eligible for inclusion. Inclusion criteria included lapa-
roscopically confirmed endometriosis (stage I–IV, using revised 
American Society of reproductive Medicine [r-ASrM] scoring) 
(15,16), which was determined at laparoscopy within 12 months 
prior to study baseline. Patients had to report at screening and 
baseline an EAPP score of at least 30 mm (study 2) or 40 mm 
(study 3) on a VAS, where 0 mm represents absence of pain 
and 100 mm indicates unbearable pain. For study 1 there was 
no minimal VAS score requirement at study entry.
Exclusion criteria included pregnancy or breast feeding, use 
of an intrauterine device, amenorrhea within three months of 
screening, signs or symptoms of therapy resistant endometrio-
sis or need for immediate surgical treatment of endometriosis, 
ent preferences of important regulatory agencies. While the 
VAS is one of the most widely used pain scales in Europe 
and was also used as a primary endpoint in studies of the 
most recently approved drug for treatment of endometrio-
sis in Europe (8), the FdA indicated a clear preference for 
the B&B score and its components (9). In Japan the most 
recent approval for an endometriosis therapy was based 
on studies using several five-point pain measurements and 
a VAS (10). While these pain scales assess the most rele-
vant clinical symptom of endometriosis they may not cover 
other important aspects of the disease. therefore, more 
comprehensive tools to assess quality of life (QoL) are 
often included in endometriosis clinical trials (5, 11), e.g. 
the SF-36 (12). this nondisease-specific QoL instrument 
has recently been validated for use in patients with endo-
metriosis (13). A subscale to assess “bodily pain” is part 
of this instrument showing a good correlation with other 
pain scales in endometriosis patients. nondisease-specific 
tools such as the SF-36 facilitate comparison of the burden 
of the disease with other illnesses. disease-specific tools 
such as the EHP-30 or -5 are generally more sensitive, but 
do not facilitate comparison across diseases. 
the aim of our work was to explore which of the most com-
monly used pain scales is most suitable to assess treat-
ment success in endometriosis therapy and, therefore, 
best qualifies for use as a primary endpoint in clinical stud-
ies for this indication. to this end, we compared different 
pain scales with the clinical Global Impression (cGI) score. 
this single item tool assesses “overall treatment success” 
without differentiation into specific symptoms or aspects 
of QoL. It qualifies perfectly as a so- called “anchor”, i.e. 
a very simple tool to compare the more complex tools 
against (14).
Specifically, we wanted to analyze (A) which pain scale re-
flects patient satisfaction best and (B) which instrument is 
most suitable to assess treatment effects. 
MAtErIALS And MEtHodS
Studies
three recent studies with a similar design used measurement of 
endometriosis-associated pelvic pain (EAPP) on a VAS as pri-
mary endpoint (Fig. 1); several other patient reported outcomes 
(Pros) were assessed as secondary endpoints. Study 1 (5) 
was a multicenter, open-label, controlled, randomized, parallel 
Fig. 1 - Visual analogue scale. 
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moderate; 3 = severe) based on the patient’s assessment of 
three distinct pain symptoms (dysmenorrhea, pelvic pain, dys-
pareunea) and on two findings obtained during gynecologic 
palpation (tenderness, induration). the three pain symptoms 
are combined with the “pelvic symptoms score” and the two 
findings with the “physical symptoms score”. Finally, both can 
be combined with the “B&B total sum score” (Fig. 2).
the cGI scale (14) originally consists of three items: severity of 
illness, efficacy index, and global improvement each an-
swered on a seven-point scale. the studies reported here 
used a patient-reported modification of the global improve-
ment item (1 = Very much satisfied; 2 = Much satisfied; 3 
= Minimally satisfied; 4 = neither satisfied nor dissatisfied; 
5 = Minimally dissatisfied; 6 = Much dissatisfied; and 7 = 
Very much dissatisfied).
the SF-36 (12) can be considered the gold standard for 
QoL measurements under different conditions, but it is not 
specific for endometriosis. It includes the assessment of 
recent use of hormonal agents (e.g., GnrH agonists ≤ 6 months 
before screening, progestins or danazol ≤ 3 months before 
screening, or oral contraceptives ≤ 1 month before screening), 
clinically relevant findings at gynecologic examination other 
than endometriosis, or an abnormal cervical cytologic smear in 
the last three months.
Endpoints
Among other clinical parameters not covered in this paper, 
the following endpoints were documented in all three stud-
ies and were used for this pooled analysis.
the VAS for EAPP (Fig. 1) is a 10 cm long horizontal line with its 
extremes marked as “absence of pain” and “unbearable pain”. 
the patient ticks her pain level on the line and the distance from 
the left extreme “absence of pain” to the tick mark is measured 
in millimeters yielding a pain score from 0 to 100.
the B&B score (4) consists of a rating (0 = none; 1 = mild; 2 = 
Fig. 2 - Biberoglu and Beh-
rman score.
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casian as all three studies were performed in Europe. Mean 
patient age was 31.4 years (± 6.3). At baseline, patients re-
ported substantial mean levels of pain symptoms on the re-
spective scales: 58.1 (± 21.9) on the VAS, 4.8 (± 1.7) for the 
B&B subscore on pelvic symptoms, and 42.3 (± 20.0) on the 
bodily pain subscale of the SF-36. there was no relevant dif-
ference in any of the baseline parameters between the treat-
ment groups, see table I.
the correlations of the different scales with regard to chang-
es from baseline to week 12 are summarized in table II. Al-
most all comparisons showed a correlation in the expected 
direction, i.e. improvement of pain assessed by one scale 
was generally positively correlated with improvement of pain 
assessed by the other scales. It is important to mention that 
the scoring system of the SF-36 assigns higher numeric 
scores to a better health status whereas all other instruments 
assign lower numeric values to less pain. Based on the Pear-
son coefficient, the highest correlation with the cGI efficacy 
index was observed for the VAS (rP=0.53) followed by the 
B&B pelvic pain item (rP=0.40) while the B&B dyspareunia 
item did not show a relevant correlation with the cGI effi-
cacy index (rP=0.19). Most scales showed a moderate cor-
relation between themselves; again with the exception of the 
B&B dyspareunia item which was not relevantly correlated 
with either B&B dysmenorrhea (rP=0.24) or SF-36 bodily pain 
(rP=-0.15). the non-parametric Spearman correlations were 
similar to the Pearson correlations for all variables except for 
SF-36 bodily pain, where rP indicated  a substantially stron-
ger correlation than the rS. Based on rS there was no relevant 
correlation between SF-36 bodily pain and any of the other 
pain scales (rS=0.03 to -0.13). 
the results presented in table II are regardless of the treat-
ment. When data were analyzed by treatment, the structure 
and magnitude of the correlations were not substantially al-
tered (data not shown).
Effect sizes of the different variables investigated are shown 
in table III for both, comparison of end-of-study versus 
baseline and comparison between treatment groups. Effect 
sizes for comparison between treatment groups ranged from 
0.24 (B&B dyspareunia) to 0.709 (B&B dysmenorrhea). the 
B&B dysmenorrhea item, B&B pelvic symptoms score, SF-
36 bodily pain, and VAS had the largest effect sizes regard-
ing the comparisons within each treatment group as well as 
between active and in-active groups. For the comparison 
between treatment groups the effect sizes of the B&B dys-
menorrhea item, B&B pelvic symptoms score, and VAS were 
0.709, 0.630, and 0.703 for SF-36 bodily pain, respectively.
symptoms that may disrupt working ability, social relation-
ships or sexual functioning. the SF-36 consists of 36 items 
combined into the eight subscales role-Emotional, Vitality, 
General Health, Mental Health, Bodily Pain, Physical Func-
tioning, role Physical, and Social Functioning. these are 
further combined into the two summary measures Mental 
Health and Physical Health. the scoring system of the SF-
36 assigns higher numeric scores to a better health status.
Statistical analysis
Efficacy and quality of life data were pooled from the three 
individual studies into one data set for statistical analyses. 
Following the “intention to treat” principle, all patients that 
provided data were included in the analyses, regardless of 
possible protocol deviations.
change from baseline was analyzed for all variables ex-
cept for the cGI which is already a measure of change. 
For the assessment of correlations of pain scales with the 
cGI the difference in score of a pain scale at each time 
point (12 or 24 weeks, respectively) versus baseline was 
compared to the cGI at the same time point. For com-
parison of effect sizes only data after 12 weeks of treat-
ment were utilized because the treatment effect can be 
expected to change over time and the PL groups were 
only treated for 12 weeks. For the B&B score only the 
patient reported outcomes dysmenorrhea, pelvic pain, 
and dyspareunea were analyzed. In addition, the  “pelvic 
symptoms score”, a summary measure of dysmenorrhea, 
pelvic pain, and dyspareunea was analyzed. In the same 
way, the analyses of the SF-36 focused on bodily pain 
subscale.
Variables were analyzed by descriptive statistics using ver-
sion 9.2 of SAS software (SAS, cary, nc, uSA www.sas.
com). Parametric, i.e. Pearson (r
P), and nonparametric, i.e. 
Spearman (rs), correlation coefficients were calculated for 
the whole population as well as separately by treatment 
assignment. Effect sizes were calculated as the mean of 
the change from baseline divided by the standard devia-
tion of the change.
rESuLtS
A total of 428 patients, 222 receiving active treatment (i.e. 
dnG) and 206 receiving inactive treatment (Et or PL), were 
included in our analyses. Most patients (98.1%) were cau-
© 2012 The Authors - ISSN 2035-9969 113
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the question used, which allows a patient to consider a 
wide range of subjective and individual symptoms  relat-
ing to this item. As a result this may be a better tool to 
assess overall treatment satisfaction than more specific 
questions. Another possible interpretation of this finding 
may be that patients care most about the overall amount 
of pain while the type of pain or subtle differences in the 
way it is worded may be less important. nevertheless, dif-
ferentiation between specific types of pain may be useful 
as secondary endpoints in clinical trials, e.g. to help under-
stand the mode of action of a specific treatment.
the VAS, as the best instrument in this respect, still ac-
dIScuSSIon
the pain and QoL scales investigated in this study are used 
to measure endometriosis-associated pain in clinical stud-
ies. In our study all scales showed the expected direction 
of correlation with the cGI efficacy index which was used 
as the anchor indicating overall treatment success in this 
analysis. However, the different scales showed substantial 
variability in their degree of correlation with the anchor tool 
and their ability to detect treatment effects. 
the superior correlation of the VAS with overall treatment 
satisfaction may result from the quite general wording of 
TAbLE I - dEMoGrAPHIcS And BASELInE ScorES
Active Inactive Total
n % n % n %
total number of patients 222  100 206 100 428 100
Ethnic group: caucasian 217  97.7 203 98.5 420 98.1
Mean Sd Mean Sd Mean Sd
Age (years) 31.0 6.4 31.9 6.1 31.4 6.3
Weight (kg) 62.44 10.52 63.15 10.89 62.78 10.69
Body Mass Index (kg/m²) 22.66 3.40 22.86 3.71 22.75 3.55
Mean Sd Mean Sd Mean Sd
Visual Analogue Scale 54.93 24.62 61.52 17.93 58.11 21.87
B&B score Pelvic pain 1.8 0.8 1.7 0.7 1.8 0.7
B&B score dysmenorrhea 1.8 0.8 1.8 0.8 1.8 0.8
B&B score dyspareunia 1.2 0.9 1.2 0.9 1.2 0.9
B&B score Induration 1.0 0.8 1.1 0.8 1.1 0.8
B&B score Pelvic tenderness 1.3 0.7 1.5 0.7 1.4 0.7
B&B subscore Sum of pelvic symptoms 4.8 1.7 4.8 1.8 4.8 1.7
B&B subscore Sum of physical signs 2.4 1.2 2.6 1.2 2.5 1.2
B&B Sum of scores 7.2 2.5 7.4 2.5 7.3 2.5
SF-36 subscale Emotional role function 57.80 40.10 63.50 41.00 59.52 40.37
SF-36 subscale Energy / Vitality 47.20 19.20 49.60 18.50 47.90 19.00
SF-36 subscale General Health 51.50 21.70 46.30 20.10 49.90 21.30
SF-36 subscale Mental health 57.70 19.20 57.80 18.90 57.71 19.04
SF-36 subscale Bodily Pain 41.00 21.50 45.30 15.60 42.30 20.00
SF-36 subscale Physical function 77.90 20.00 78.40 18.00 78.03 19.41
SF-36 subscale Physical role function 49.20 38.90 55.30 37.90 51.00 38.60
SF-36 subscale Social function 64.60 24.10 65.00 21.80 64.75 23.39
SF-36 summary measure Physical Health 49.98 8.76 49.99 8.76 50.00 8.72
SF-36 summary measure Mental Health 49.90 10.25 50.01 10.33 49.94 10.30
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counts for only 28% of the variability in patient’s satis-
faction with treatment (coefficient of determination r2 
= 0.28). In contrast, the SF-36 only accounts for 16% of 
the variability. this strongly supports the need to include 
validated disease-specific QoL tools to assess aspects 
of endometriosis other than pain. An example of such a 
tool is the EHP-30 and its short-form the EHP-5. other 
tools are currently being developed following the recently 
published FdA guidance on development of Pro instru-
ments (16 and VALEPro study, clinicaltrials.gov Identifier: 
nct01643122). However, these tools were not available at 
the time the reported trials were performed. 
TAbLE II - corrELAtIonS BEtWEEn tHE cHAnGE FroM BASELInE BEtWEEn dIFFErEnt PAIn ScorES 
Pearson
Spearman
CGI, efficacy 
index
VAS b&b 
dysmenorrhea
b&b 
dyspareunia
b&b 
pelvic
pain
b&b 
subscore 
pelvic 
symptoms
SF-36 
bodily
pain
cGI, efficacy index 0.53 0.35 0. 19 0.40 0. 39 -0.40
VAS 0.56 0.47 0.15 0.40 0.47 -0.50
B&B dysmenorrhea 0.37 0.51 0.24 0.38 0.78 -0.47
B&B dyspareunia 0.17 0.11 0.16 0.27 0.67 -0.15
B&B pelvic pain 0.40 0.36 0.31 0.28 0.73 -0.32
B&B subscore pelvic symptoms 0.40 0.49 0.76 0.62 0.70 -0.46
SF-36 bodily pain -0.13 -0.12 0.03 0.01 -0.12 -0.06
cGI, clinical global impression; VAS, visual analog scale
TAbLE III - EFFEct SIZES For cHAnGES FroM BASELInE
Variable Treatment n Mean SD Effect size
Visual Analog Scale Active treatment 210 -31.890 30.340 -1.051
Inactive treatment 185 -19.330 21.128 -0.915
Active - Inactive 395 -12.561 26.363 -0.476
B&B dysmenorrhea Active treatment 214 -1.252 1.101 -1.137
Inactive treatment 194 -0.552 0.852 -0.648
Active - Inactive 408 -0.701 0.988 -0.709
B&B dyspareunea Active treatment 190 -0.611 0.906 -0.674
Inactive treatment 166 -0.410 0.755 -0.542
Active - Inactive 356 -0.201 0.837 -0.240
B&B pelvic pain Active treatment 214 -0.907 0.834 -1.087
Inactive treatment 194 -0.552 0.802 -0.688
Active - Inactive 408 -0.355 0.817 -0.435
B&B pelvic symptoms Active treatment 190 -2.732 2.010 -1.359
Inactive treatment 166 -1.554 1.707 -0.910
Active - Inactive 356 -1.177 1.870 -0.630
SF-36 bodily pain Active treatment 212 28.245 27.523 1.026
Inactive treatment 91 10.286 20.499 0.502
Active - Inactive 303 17.960 25.540 0.703
Sd, standard deviation
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studies which may introduce a higher degree of variability 
compared to data obtained from one study.
Summary and recommendation
Based on our analysis, a general measure of endometri-
osis-related pain (VAS/nrS) best reflects patient’s overall 
satisfaction with treatment and can be recommended as 
primary endpoint in clinical trials to assess painful symp-
toms of endometriosis. daily electronic assessment to-
gether with a bleeding diary would enable differentiating 
between pain related or not related to bleeding without the 
risk of narrowing down the scope of the question. In addi-
tion, a disease-specific QoL instrument is recommended 
in order to allow interpretation of the impact on patient’s 
daily activities. Potentially, this needs to be applied less 
frequently than questions on pain. 
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